Overview

* Medifast ( MED ) Q3 revenue falls 36.2% yr/yr due to fewer active earning coaches

* Company reports Q3 net loss of $2.3 mln, compared to net income last year

* Medifast ( MED ) maintains strong balance sheet with $173.5 mln in cash, no debt

Outlook

* Company expects Q4 2025 revenue between $65 mln and $80 mln

* Company projects Q4 2025 diluted loss per share between $0.70 and $1.25

Result Drivers

* COACH DECLINE - Revenue decrease primarily driven by 35% drop in active earning OPTAVIA coaches

* GLP-1 IMPACT - Challenges in client acquisition due to acceptance of GLP-1 medications for weight loss

* STRATEGIC TRANSFORMATION - Co is shifting focus to metabolic health, aiming for larger market

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $89.40

Revenue mln

Q3 EPS -$0.21

Q3 Net -$2.26

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the food processing peer group is "buy."

* Wall Street's median 12-month price target for Medifast Inc ( MED ) is $15.00, about 19.9% above its October 31 closing price of $12.02

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)